Reference drugs for triple combination test drug in Russia [Design Issues]

posted by PharmCat  – Russia, 2019-11-13 22:25 (1795 d 07:52 ago) – Posting: # 20801
Views: 6,142

❝ i.e. 2 tablets. All of these drugs are reference drugs according to the GRLS system.

❝

❝ What is your opinion which option to choose?


Hello!

Strictly for bioequivalence you should chose drug from register that have label "Reference drug". If no such drug - you should make
efficacy trial.

I heard there was a case when drug was registered in EU and BE in Russia was performed with separate reference drugs - but now this case is not approvable, but some companies try to do this.

If say strict - both cases is wrong.

Complete thread:

UA Flag
Activity
 Admin contact
23,249 posts in 4,885 threads, 1,665 registered users;
68 visitors (0 registered, 68 guests [including 10 identified bots]).
Forum time: 07:17 CEST (Europe/Vienna)

I believe there is no philosophical high-road in science,
with epistemological signposts. No, we are in a jungle
and find our way by trial and error,
building our road behind us as we proceed.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5